|
End-of-day quote
Nasdaq
17/11/2026
|
5-day change | 1st Jan Change | ||
| 1.720 USD | -8.99% |
|
+2.99% | -80.95% |
| 11-16 | EnGene Therapeutics Inc. Presents at UBS Global Biopharma Conference 2026, Nov-16-2026 03:20 PM | |
| 11-13 | Leerink Partners Upgrades enGene to Outperform From Market Perform, $5 Price Target | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.99% | +2.99% | +2.99% | +1.18% | -80.95% | -78.66% | -77.52% | - | - | 115M | ||
| +1.15% | -2.81% | +1.23% | -12.48% | +61.15% | +55.79% | +71.12% | +6.97% | - | 66.37B | ||
| +1.12% | -1.33% | +18.36% | -0.71% | +20.51% | +9.54% | +91.66% | +232.10% | +6,182.18% | 58.86B | ||
| +1.12% | +0.93% | +9.23% | +18.38% | +24.54% | +26.57% | +87.51% | -9.78% | +267.01% | 55.22B | ||
| +0.48% | -2.53% | +11.98% | +14.00% | +36.03% | +9.73% | +121.14% | +8.72% | +1,163.79% | 47.21B | ||
| -2.69% | -6.38% | -3.48% | +6.78% | +14.28% | +19.19% | +25.79% | -2.59% | +224.11% | 42.45B | ||
| -0.70% | +4.93% | +9.79% | +5.97% | +23.56% | +17.77% | +45.03% | +18.30% | +191.74% | 36.44B | ||
| -2.50% | -15.73% | -8.58% | -23.26% | +104.26% | +135.31% | +662.73% | +424.98% | - | 35.19B | ||
| +0.11% | -1.49% | +38.00% | +66.73% | +73.06% | +83.09% | +58.02% | +25.82% | +181.54% | 32.66B | ||
| -0.83% | +1.98% | +26.58% | -5.03% | -29.98% | -38.27% | +390.98% | +301.52% | +721.16% | 26.73B | ||
| -3.59% | -8.67% | -10.81% | -8.11% | +41.98% | +39.94% | -7.00% | -59.89% | - | 24.22B | ||
| -0.47% | -2.69% | -3.25% | -7.36% | -10.86% | -17.35% | -14.62% | -68.80% | - | 21.04B | ||
| +0.75% | -1.72% | +5.60% | +9.37% | +16.28% | +11.49% | +138.35% | +187.19% | +1,721.22% | 18.27B | ||
| -0.20% | +5.69% | +20.40% | +9.62% | - | - | - | - | - | 17.79B | ||
| +0.35% | -2.57% | +8.61% | +23.08% | +37.40% | +49.11% | +66.81% | -20.54% | +103.20% | 16.08B | ||
| +2.09% | -2.95% | +10.08% | +30.93% | +56.29% | +61.48% | +224.18% | +283.11% | +308.96% | 16.71B | ||
| -1.16% | 0.00% | +2.81% | -9.22% | +202.10% | +204.04% | +335.27% | +1,001.87% | +756.35% | 16.1B | ||
| -1.00% | -3.94% | +10.66% | +15.88% | +66.51% | +104.10% | +75.71% | -15.50% | +350.63% | 15.92B | ||
| +1.89% | -4.70% | +14.60% | +15.09% | +7.02% | +24.62% | -27.76% | -30.70% | +152.55% | 14.61B | ||
| -2.35% | -7.62% | -9.36% | -21.81% | +8.16% | -2.39% | +367.44% | - | - | 13.23B | ||
| Average | -0.77% | -3.13% | +7.77% | +6.45% | +35.33% | +37.64% | +138.68% | +134.28% | +948.03% | 29B | |
| Weighted average by Cap. | -0.18% | -2.62% | +8.42% | +6.00% | +39.79% | +39.46% | +138.12% | +108.02% | +1,343.01% |
- Stock Market
- Stocks
- ENGN Stock
- Sector enGene Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
















